Tranexamic acid can inhibit tongue squamous cell carcinoma invasion in vitro

Oral Diseases

Volumn 15, Issue 2, 2009, Pages 170-175

  Suojanen, J ^a,b   Sorsa, T ^a   Salo, T ^b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF OULU   (Finland)

Author keywords

Human tongue squamous cell carcinoma; Invasion; Migration; MMP 9; Tranexamic acid

Indexed keywords

CTT1 PEPTIDE; GELATIN; GELATINASE B; GELATINASE INHIBITOR; MATRIGEL; PLASMIN; TRANEXAMIC ACID; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CANCER INVASION; CELL ASSAY; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME SYNTHESIS; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TONGUE CARCINOMA; WESTERN BLOTTING; ZYMOGRAPHY;

ANTIFIBRINOLYTIC AGENTS; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL MOVEMENT; ENZYME INHIBITORS; ENZYME PRECURSORS; GELATINASES; HUMANS; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; PEPTIDES, CYCLIC; TONGUE NEOPLASMS; TRANEXAMIC ACID; TUMOR CELLS, CULTURED;

EID: 60349125969     PISSN: 1354523X     EISSN: 16010825     Source Type: Journal    
DOI: 10.1111/j.1601-0825.2008.01507.x     Document Type: Article

References (39)

1. Andreasen PA, Kjoller L, Christensen L, Duffy MJ (1997). The urokinase plasminogen acivator system in cancer metastasis: a review. Int J Cancer 72 : 1 22.
2. 2-macroglobulin secretion. Cell Regul 1 : 895 905.
3. Chapman HA (1997). Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Curr Opin Cell Biol 9 : 714 724.
4. Choong PFM, Nadesapillai APW (2003). Urokinase plasminogen activator system- a multifunctional role in tumour progression and metastasis. Clin Orthop Relat Res 415S : 46 58.
5. Clayman G, Wang SW, Nicolson GL et al (1993). Regulation of urokinase-type plasminogen activator expression in squamous-cell carcinoma of the oral cavity. Int J Cancer 54 : 73 80.
6. Cox S, Cole M, Mankarious S, Tawil N (2003). Effect of tranexamic acid incorporated in fibrin sealant clots on the cell behaviour of neuronal and nonneuronal cells. J Neurosci Res 72 : 734 746.
7. Curino A, Patel V, Nielsen BS et al (2004). Detection of plasminogen activators in oral cancer by laser capture microdissection combined with zymography. Oral Oncol 40 : 1026 1032.
8. Devy L, Noel A, Baramova E et al (1997). Production and activation of matrix metalloprotease-9 (MMP-9) by HL-60 promyelocytic leukemia cells. Biochem Biophys Res Commun 238 : 842 846.
9. Devy L, Rabbani SA, Stochl M et al (2007). PEGylated DX-1000: pharmacokinetics and antineoplastic activity of a specific plasmin inhibitor. Neoplasia 9 (Suppl. 11 927 937.
10. Dowd NP, Karski JM, Cheng DC et al (2002). Pharmacokinetics of tranexamic acid during cardiopulmonary bypass. Anesthesiology 97 : 390 399.
11. Dunn CJ, Goa KL (1999). Tranexamic acid, a review of its use in surgery and other indications. Drugs 57 (Suppl. 6 1005 1032.
12. Festuccia C, Dolo V, Guerra F et al (1998). Plasminogen activator sysytem modulates invasive capacity and proliferation in prostatic tumor cells. Clin Exp Metastasis 16 : 513 528.
13. Frachon X, Pommereuil M, Berthier A-M et al (2005). Management options for dental extraction in hemophiliacs: a study of 55 extractions (2000-2002). Oral Surg Oral Med Oral Pathol Oral Radiol Endod 99 (Suppl. 3 270 275.
14. Gosalia DN, Denney WS, Salisbury CM, Ellman JA, Diamond SL (2006). Functionl phenotyping of human plasma using a 361-fluorogenic substrate microarray. Biotechnol Bioeng 94 (Suppl. 6 1099 1110.
15. Hall JE (2006). Medical physiology, 11th edn. Saunders : Philadelphia, PA, pp. 457 468.
16. Hasina R, Hulett K, Bicciato S et al (2003). Plasminogen activator inhibitor-2: a molecular biomarker for head and neck cancer progression. Cancer Res 63 : 555 559.
17. Heikkilä P, Suojanen J, Pirilä E et al (2006). Human tongue carcinoma growth is inhibited by selective antigelatinolytic peptides. Int J Cancer 118 : 2202 2209.
18. Hervio LS, Coombs GS, Bergstrom RC, Trivedi K, Corey DR, Madison EL (2000). Negative selectivity and the evolution of protease cascades: the specificity of plasmin for peptide and protein substrates. Chem Biol 7 (Suppl. 6 443 452.
19. Hong S-D, Hong S-P, Lee J-I, Lim C-Y (2000). Expression of matrix metalloproteinase-2 and -9 in oral squamous cell carcinomas with regard to the metastatic potential. Oral Oncol 36 : 207 213.
20. Juarez J, Clayman G, Nakajima M et al (1993). Role and regulation of expression of 92-kDa type-IV collagenase (MMP-9) in 2 invasive squamous-cell-carcinoma cell lines of the oral cavity. Int J Cancer 55 : 10 18.
21. Karski JM, Teasdale SJ, Norman P et al (1995). Prevention of bleeding after cardiopulmonary bypass with high-dose tranexamic acid. J Thorac Cardiovasc Surg 110 (Suppl. 3 835 842.
22. Kikuchi Y, Kizawa I, Oomori K, Kuki E, Kato K (1986). The inhibitory effect of tranexamic acid on human ovarian carcinoma cell growth in vitro and in vivo. Gynecol Oncol 24 : 183 188.
23. Kodama Y, Tanaka K (1981). Effect of tranexamic acid on the growth and metastasis of V2 carcinoma in rabbits. Gann 72 : 411 416.
24. Koivunen E, Arap W, Valtanen H et al (1999). Tumor targeting with a selective gelatinase inhibitor. Nat Biotechnol 17 : 768 774.
25. Lacroix M, Marie PJ, Body J-J (2000). Protein production by osteoblasts: modulation by breast cancer cell-derived factors. Breast Cancer Res Treat 61 : 59 67.
26. Moilanen M, Pirilä E, Grenman R et al (2002). Expression and regulation of collagenase-2 (MMP-8) in head and neck squamous cell carcinomas. J Pathol 197 : 72 81.
27. Murthi P, Barker G, Nowell CJ et al (2004). Plasminogen fragmentation and increased production of extracellular matrix-degrading proteinases are associated with serous epithelial ovarian cancer progression. Gynecol Oncol 92 : 80 88.
28. Nyberg P, Heikkilä P, Sorsa T et al (2003). Endostatin inhibits human tongue carcinoma cell invasion and intravasation and blocks the activation of matrix metalloproteinase -2, -9, and -13. J Biol Chem 278 (Suppl. 25 22404 22411.
29. Ra H-J, Parks WC (2007). Control of matrix metalloproteinase catalytic activity. Matrix Biol 26 : 587 596.
30. Ramos DM, Chen BL, Boylen K et al (1997). Stromal fibroblasts influence oral squamous-cell carcinoma cell interactions with tenascin-C. Int J Cancer 72 : 369 376.
31. Rang HP, Dale MM, Ritter MM (1999). Pharmacology, 4th edn. Churchill Livingstone : Edinburgh, UK, pp. 325 326.
32. Rosenthal EL, Matrisian LM (2006). Matrix metalloproteinases in head and neck cancer. Head Neck 28 : 639 648. doi :.
33. Ruokolainen H, Pääkkö P, Turpeenniemi-Hujanen T (2005). Serum matrix metalloproteinase-9 in head and neck squamous cell carcinoma is a prognostic marker. Int J Cancer 116 : 422 427.
34. Stonelake PS, Jones CE, Neoptolemos JP, Baker PR (1997). Proteinase inhibitors reduce basement membrane degradation by human breast cancer cell lines. Br J Cancer 75 (Suppl. 7 951 959.
35. Tang E-H, Friess H, Kekis PB et al (2001). Serine protease activation in esophageal cancer. Cancer Res 21 : 2249 2258.
36. Teodorczyk-Injeyan J, Falk R, Ng RWH, Kellen JA (1983). The effect of tranexamic acid on growth and spread of an experimental tumor model. Res Commun Chem Pathol Pharmacol 39 (Suppl. 3 515 518.
37. Väänänen A, Srinivas R, Parikka M et al (2001). Expression and regulation of MMP-20 in human tongue carcinoma cells. J Dent Res 80 : 1884 1889.
38. Webster K, Wilde J (2000). Management of anticoagulation in patients with prosthetic heart valves undergoing oral and maxillofacial operations. Br J Oral Maxillofac Surg 38 : 124 126.
39. Yaniv E, Shvero J, Hadar T (2006). Hemostatic effect of tranexamic acid in elective nasal surgery. Am J Rhinol 20 : 227 229.